Late effects of adjuvant therapy for breast cancer.
Shapiro
C L
CL
Breast Evaluation Center, Dana-Farber Cancer Institute, Boston, Mass 02125.
Recht
A
A
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy / Q000628:therapy*; D009202:Cardiomyopathies / Q000209:etiology*; D016022:Case-Control Studies; D017024:Chemotherapy, Adjuvant / Q000009:adverse effects; D015331:Cohort Studies; D003131:Combined Modality Therapy / Q000009:adverse effects; D016889:Endometrial Neoplasms / Q000139:chemically induced / Q000453:epidemiology; D005260:Female; D006801:Humans; D015994:Incidence; D015470:Leukemia, Myeloid, Acute / Q000453:epidemiology / Q000209:etiology; D007953:Leukemia, Radiation-Induced / Q000209:etiology; D008207:Lymphatic Metastasis; D015201:Meta-Analysis as Topic; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D009381:Neoplasms, Radiation-Induced / Q000209:etiology*; D016609:Neoplasms, Second Primary / Q000453:epidemiology / Q000209:etiology*; D016649:Primary Ovarian Insufficiency / Q000139:chemically induced; D018714:Radiotherapy, Adjuvant / Q000009:adverse effects*; D016032:Randomized Controlled Trials as Topic; D012509:Sarcoma / Q000453:epidemiology / Q000209:etiology; D013629:Tamoxifen / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome
D013629:Tamoxifen